Building products supplier Wagners has taken its largest cement customer, Boral, to court in a dispute over pricing, and will take a $10 million hit to its 2019 earnings as a result.
After losing its fight for a temporary injunction, Sanofi-Aventis has dropped its patent lawsuit against Alphapharm over the generic drug maker’s plans to market a competing insulin injector pen in Australia.
A shareholder class action against Woolworths related to its downward revision of a 2015 profit guidance is seeking emails and other documents from a slew of current and former company executives, including the grocery chain’s former Chairman and CEO, who departed in the wake of disappointing financial results.
A former in-house counsel for eBay that has resorted to waiting tables after losing his job following the publication of defamatory material by a US gun dealer implying he’s a hacker who lied about his legal credentials has been awarded $875,000 in damages.
After putting to rest a trademark dispute with the Taronga Zoo, the still unopened Sydney Zoo is facing another legal challenge from a competing zoo alleging it is threatening to violate the terms of its development consent.
An appeals court has revived a class action against a NSW council over loss and damage resulting from a 2009 tip rubbish fire, and awarded the lead applicant over $100,000 in damages.
Construction giant Lendlease has been hit with a class action over allegedly inadequate disclosures relating to its engineering and services business, which includes the NorthConnex tunnel road project in Sydney.
Ticket reseller Viagogo will face penalties after the court found it duped customers into thinking it was an official ticket vendor and failed to disclose booking fees of around 28 per cent, causing some customers to pay hundreds of dollars more than what their tickets were actually worth.
Horse vaccine maker Zoetis has appealed a ruling that denied its request for $450,000 as security for costs in an unfunded class action accusing it of failing to warn about the vaccine’s side effects.
Apple founder Steve Jobs’ penchant for using the phrase “One more thing” as a rhetorical flourish during his highly anticipated “Stevenote” talks — usually before unveiling a new Apple product — does not constitute a trade mark use, according to a decision quashing Apple’s opposition to watch maker’s Swatch’ application to trade mark the phrase in Australia.